Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06269510 · ClinicalTrials.gov registry record · NA

Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients

A NA study of Liver Diseases and Alcohol-related Liver Disease, sponsored by Henry Ford Health System.

Recruiting
Registry status
NA
Development phase
268
Enrollment target
1
Study location

NCT06269510: Recruiting NA study of Liver Diseases and Alcohol-related Liver Disease, sponsored by Henry Ford Health System.

NCT06269510 is a NA study of Liver Diseases and Alcohol-related Liver Disease that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 268 participants, below the 61,150-participant average among 33 other Liver Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06269510, a NA study of Liver Diseases and Alcohol-related Liver Disease, is actively recruiting participants, sponsored by Henry Ford Health System.

RECRUITING
Registry status
NA
Development phase
268 participants
Enrollment target
1
Study location

Study Summary

The purpose of this trial is to see if providing patients with alcohol-related liver disease with tailored alcohol use treatment options will increase engagement with treatment and correct possible misconceptions.

Primary Outcome

Measured using self-report and defined as any single session (in-person or virtual) of the following: * Professional mental health counselor led one-on-one therapy, group therapy, couples, or family therapy with a primary aim of alcohol abstinence or reduction in alcohol use. * Community-based alcohol recovery groups (such as Alcoholics Anonymous, Self-Management and Recovery Training (SMART) Recovery, Celebrate Recovery, Refuge Recovery) * Community-based church support groups primarily focuse

Interventions

  • BEHAVIORAL Enhanced Usual Care
  • BEHAVIORAL ENGAGE-ALD Application (APP)
  • BEHAVIORAL Treatment Facilitation bundle

Study Locations (1)

Michigan

  • Henry Ford Health - Detroit

Trial Details

FieldValue
Enrollment Target 268 participants
Start Date 2026-01-28
Est. Completion 2030-02
Phase NA
Henry Ford Health System

234 total trials

What NCT06269510 shows while recruiting

NCT06269510 is an interventional study that assigns participants to a tested intervention. The registered 268 participants enrollment target is mid-sized for trials with a published cap, below the 61,150-participant average among 33 other Liver Diseases trials with a reported enrollment target (100% lower).

The record links to 2 conditions, with Liver Diseases appearing as the primary indexed condition, and to 3 interventions - of which Enhanced Usual Care is the first listed.

NCT06269510 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT06269510 about?

NCT06269510 is a clinical study titled "Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients". The purpose of this trial is to see if providing patients with alcohol-related liver disease with tailored alcohol use treatment options will increase engagement with treatment and correct possible misconceptions.

What is the current status of trial NCT06269510?

This trial is currently recruiting. It is a NA study. The enrollment target is 268 participants. The study started on 2026-01-28. Estimated completion is 2030-02.

What conditions does trial NCT06269510 study?

This clinical trial studies the following conditions: Liver Diseases, Alcohol-related Liver Disease.

What interventions are being tested in trial NCT06269510?

The interventions under investigation include: Enhanced Usual Care (BEHAVIORAL), ENGAGE-ALD Application (APP) (BEHAVIORAL), Treatment Facilitation bundle (BEHAVIORAL).

Who is sponsoring clinical trial NCT06269510?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06269510 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Liver Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06269510's enrollment target sits among peer trials

268 14th of 33 higher than 20 of 33 other Liver Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Liver Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05000632 · 268 participants · NA

    Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families

  • NCT05797831 · 268 participants · Phase 2

    Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  • NCT05997381 · 268 participants · NA

    BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears

  • NCT06233461 · 268 participants · Phase 2

    A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06269510, the US trial registry maintained by the National Library of Medicine. NCT06269510 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.